- Home
- CRSP vs MDA Comparison
CRSP vs MDA Comparison
Compare CRSP & MDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRSP | MDA |
|---|---|---|
| Founded | 2013 | 1969 |
| Country | Switzerland | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electronic Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 3.8B |
| IPO Year | 2016 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CRSP | MDA |
|---|---|---|
| Price | $46.25 | $31.40 |
| Analyst Decision | Buy | |
| Analyst Count | 17 | 0 |
| Target Price | ★ $70.29 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 895.2K |
| Earning Date | 05-05-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,590,000.00 | N/A |
| Revenue This Year | $1,082.59 | $9.54 |
| Revenue Next Year | $87.74 | $13.02 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $30.06 | $30.35 |
| 52 Week High | $78.48 | $33.66 |
Technical Indicators
Market Signals| Indicator | CRSP | MDA |
|---|---|---|
| Relative Strength Index (RSI) | 37.01 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $60.63 | N/A |
| Average True Range (ATR) | 2.49 | 0.00 |
| MACD | -1.08 | 0.00 |
| Stochastic Oscillator | 1.70 | 0.00 |
Price Performance
Historical ComparisonAbout CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.